Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

This Amended and Restated Employment Agreement (this “Agreement”), is made and entered into on August 27, 2020 (the
“Effective Date”), by and among Cushman & Wakefield Global, Inc. (the “Employer”), Cushman & Wakefield plc (“Parent”, and, as the context requires, together with the Employer and
their respective subsidiaries, affiliates, predecessors, successors and assigns, the “Company”) and Brett White (“Executive”). 

WHEREAS, Executive is party to an employment agreement dated as of June 8, 2018, as amended from time to time in accordance with its
terms (the “Original Employment Agreement”); and 
 WHEREAS, the parties desire to enter into this Agreement to update the
terms of the Original Employment Agreement to reflect the terms and conditions governing the Executive’s employment with the Company. 

NOW THEREFORE, in consideration of the promises and mutual covenants and agreements contained herein, the adequacy of all of which
consideration is hereby acknowledged, the parties hereby agree as follows: 
 1. EMPLOYMENT 

1.1 Agreement and Term. From and after the Effective Date, the Company hereby agrees to continue to employ Executive as its Chief
Executive Officer, and Executive hereby accepts such employment and agrees to render such services to the Company, on the terms and conditions set forth in this Agreement. Unless terminated earlier as set forth in Section 3
herein, Executive’s employment and the term under this Agreement shall commence on the Effective Date and shall end on December 31, 2023 (such period of employment, the “Term”). 

1.2 Position and Duties. Except as otherwise provided in this Agreement, during the Term of this Agreement, Executive shall
serve as the Chief Executive Officer of the Company and shall report directly to the Parent Board of Directors (the “Board of Directors”), and during his employment, Executive shall serve as Executive Chairman of the Board of
Directors. Executive shall perform duties, undertake the responsibilities, and exercise the authorities customarily performed, undertaken and exercised by persons situated in the chief executive officer role at a similar company. Executive shall
carry out his duties and responsibilities at all times in compliance with the Company’s written-policies and procedures, as in effect from time to time. During the Term of this Agreement, Executive shall use his best efforts to serve the
Company faithfully, diligently and competently and to the best of his ability, and to devote the requisite amount of time (as determined by the Board after a good faith consultation with Executive) and business hours, energy, ability, attention and
skill to the business of the Company; provided, however, that the foregoing is not intended to preclude Executive from noncompetitive activities that are conducted outside normal business hours and permitted under
Section 1.3 hereof. Executive acknowledges that he may be required to travel (in accordance with Company travel policies as may be in place from time to time) as necessary in order to perform his duties and responsibilities
hereunder. 

 1.3 Outside Activities. During the Term of this Agreement, (i) with the
prior written consent of the Board of Directors, Executive may serve on the board of directors of a for-profit entity and as a director or advisor of other not-for-profit educational, welfare, social, religious and civic organizations, and (ii) Executive may perform charitable and other activities, and manage his personal investments; provided,
however, that in the case of either (i) or (ii) such activities do not interfere with the performance of his duties hereunder and otherwise to the Company and are not in conflict or competitive with, or adverse to, the interests of the
Company or any of its affiliates (together and each individually, the “Company Group”). Executive shall not, under any circumstances, provide services or advice in any capacity whatsoever for or on behalf of any entity that competes
with or is competitive with the Company Group. 
 1.4 Relocation. During the Term of this Agreement, Executive’s
principal place of employment will be relocated from Los Angeles, California, to Dallas, Texas. Executive hereby acknowledges and agrees that such relocation was at Executive’s sole and voluntary request and, as such, does not constitute Good
Reason pursuant to the Original Employment Agreement or any other agreement between Executive and any member of the Company Group. 
 2.
COMPENSATION AND BENEFITS; EXPENSES 
 2.1 Salary. During the Term of this Agreement, the Company shall compensate and pay
Executive for his services at a rate equivalent to $950,000 per year (“Base Salary”), less payroll deductions and all required tax withholdings, which salary shall be payable in accordance with the Company’s customary payroll
practices applicable to its executives, but no less frequently than monthly. Base Salary shall be subject to periodic review and possible increase by the Board of Directors based on individual and Company performance, but Executive’s Base
Salary shall not be reduced below $950,000 per year, except as provided for in that certain Voluntary Waiver Agreement, dated as of April 16, 2020, by and among the Company and Executive. 

2.2 Bonus. With respect to each fiscal year of the Company ending during the Term and subject to the achievement of any
applicable performance goals, based on corporate, business unit and/or individual performance, which performance goals are to be established by the Board of Directors after good faith consultation with Executive, Executive shall be entitled to
participate in the Company’s annual incentive plan, as such, and on such terms and conditions as, may be established by the Board of Directors from time to time, under which Executive shall be eligible to earn an annual bonus (the
“Annual Bonus”) with a target amount equal to $2,000,000 (the “Target Bonus”), with a maximum possible Annual Bonus equal to $4,000,000, and in any case subject to Executive being employed with the Company on the
date that the Annual Bonus is paid (except as described in Section 3 below). 
 2.3 Employee
Benefits. During the Term of this Agreement, to the extent eligible under the applicable plans or programs, Executive shall be entitled to participate in the employee benefits plans and programs made available to executive level employees of the
Company generally, such as health, medical, dental and other insurance coverage and group retirement plans. The terms and conditions of Executive’s participation in any employee benefit plan or program shall be subject to the terms and
conditions of such plan or program, as may be modified by the Company from time to time. Nothing in this Agreement shall preclude the Company from amending or terminating any employee benefit plan or program. 

  
 2 

 2.4 Equity. 

(a) Annual Equity Grant. On or before March 15 of each of 2021, 2022 and 2023, subject to Executive remaining employed with the
Company as Chief Executive Officer or providing services to the Company as a member of the Board of Directors as of such date, the Board of Directors will grant to Executive an award of RSUs (each, an “Equity Grant” and,
collectively, the “Equity Grants”), and each such annual award of RSUs will be subject to the terms of the Company’s customary RSU Grant Agreement (the “RSU Grant Agreement”) for employees or directors
of the Company, as applicable. The number of shares of the Company (“Common Shares”) underlying the Equity Grants will be an amount equal to (x) a dollar value not less than ten million dollars ($10,000,000) and not greater
than fifteen million dollars ($15,000,000), with such value determined by the Board of Directors in its sole discretion divided by (y) the then-current fair market value of a Common Share on the date of grant, as determined by the Board
of Directors in good faith. With respect to each Equity Grant made to Executive in his capacity as of the grant date as Chief Executive Officer of the Company or as Executive Chairman of the Board of Directors, the RSUs shall vest over a three
(3)-year vesting period, with 50% of the RSUs subject to time-based vesting conditions and 50% subject to performance-based vesting conditions, as set forth in the applicable RSU Grant Agreement, with such ratio potentially subject to change in the
Board of Directors’ discretion and subject to Executive’s consent to such change. With respect to any Equity Grant made to Executive, where on the grant date he serves solely as a member of the Board of Directors (and not as Executive
Chairman), the RSUs shall vest in accordance with the vesting terms applicable to RSU grants made to similarly-situated members of the Board of Directors or such other vesting terms as the Board of Directors may determine in its sole discretion.

 (b) Repurchase Rights and Stockholders’ Agreement. As of the Effective Date, the Company shall no longer have any repurchase
right with respect to, and that certain DTZ Jersey Holdings Limited Management Stockholders’ Agreement, dated as of May 8, 2015, by and between the parties hereto (the “Stockholders’ Agreement”), shall cease to apply
to, the RSUs granted to Executive in fiscal years 2018, 2019 and 2020. The Stockholders Agreement shall also not apply to the Equity Grants. 

2.5 Business Expenses. During the Term of this Agreement, the Company shall reimburse Executive or otherwise provide for or pay
for reasonable out-of-pocket expenses incurred by Executive in furtherance of or in connection with the business of the Company, including, but not limited to, travel
and entertainment expenses commensurate with his duties hereunder (including attendance at industry conferences), subject to the Company’s policies as periodically reviewed by the Board of Directors and in effect from time to time, including
without limitation such reasonable documentation and other limitations as may be established or required by the Company. 

  
 3 

 3. TERMINATION 

3.1 Notice of Termination. With the exception of termination of Executive’s employment due to Executive’s death, any
purported termination of Executive’s employment during the Term of this Agreement by the Company for any reason, including without limitation for Cause or Disability, or by Executive for any reason, shall be communicated by a written
“Notice of Termination” to the other party. “Notice of Termination” means a dated notice that (i) indicates the specific termination provision in this Agreement relied upon, (ii) specifies a Termination Date;
provided, however, that Executive or the Company has been provided with any applicable cure period, and (iii) is given in the manner specified in Section 5.2 hereof. “Termination Date”
means (i) if Executive’s employment is terminated for Cause or Disability, the date specified in the Notice of Termination, (ii) in the case of termination of employment due to death, the date of Executive’s death, or
(iii) if Executive’s employment is terminated for any other reason, the date on which a Notice of Termination is given or as specified in such Notice of Termination which, in the event of a termination by Executive, shall not be less than
ninety (90) days after such Notice of Termination, unless otherwise agreed to by the parties. For purposes of clarification, the Term shall end on the Termination Date. 

3.2 Termination Due to Death or Disability. If Executive’s employment and the Term is terminated by reason of
Executive’s death or Disability, Executive or his estate shall be entitled to receive: (a) Executive’s earned but unpaid Base Salary through the Termination Date; (b) an amount for reimbursement, paid within thirty (30) days
following submission by Executive (or if applicable, Executive’s estate) to the Company of appropriate supporting documentation for any unreimbursed business expenses properly incurred prior to the Termination Date by Executive pursuant to
Section 2.5 and in accordance with Company policy; (c) any earned and unused vacation, paid when required by applicable law and no later than thirty (30) days following the Termination Date; and (d) such
employee benefits, if any, to which Executive (or, if applicable, Executive’s estate) or his dependents may be entitled under the employee benefit plans or programs of the Company, paid in accordance with the terms of the applicable plans or
programs (the amounts described in clauses (a) through (d) hereof being referred to as the “Accrued Rights”). Notwithstanding anything to the contrary in Section 2.2, Executive or his estate shall
receive Executive’s Annual Bonus for the fiscal year in which the Termination Date occurs under this Section 3.2, based on actual performance results for such fiscal year and paid on the date that the Annual Bonus
would otherwise have been paid had Executive remained employed on such date. Notwithstanding anything to the contrary in any incentive equity award agreement, by and between Executive, Parent and/or Employer (each, an “Equity
Agreement” and collectively, the “Equity Agreements”), as applicable, the DTZ Management Equity Incentive Plan (the “DTZ Plan”) or any other agreement between Executive and the Company, Executive (or if
applicable, Executive’s estate) shall be allowed to exercise any vested stock options granted to Executive in fiscal year 2015 for a period of up to one (1) year following the Termination Date. For purposes hereof,
“Disability” means Executive’s incapacity due to physical or mental illness or injury as determined in writing and in good faith by a qualified independent physician, mutually acceptable to Executive and the Company, that the
Executive shall have been unable to perform his duties hereunder for a period of ninety (90) consecutive days or one hundred twenty (120) days during any consecutive one hundred eighty (180) day period. If the Company and Executive
cannot agree to a qualified independent physician within the ten (10) day period following the commencement of the Company’s process hereunder, each shall appoint a physician no later than five (5) days following the end of such ten
(10) day period and those two (2) physicians shall promptly select a third (3rd) physician, who shall make the determination whether Executive is Disabled. 

  
 4 

 3.3 Termination by the Company for Cause. In the event the Company terminates
Executive’s employment and the Term for Cause, subject to cure as described below, Executive shall be entitled to receive the Accrued Rights. “Cause” means: (i) a material breach by Executive of this Agreement, the
agreements governing Executive’s equity awards, or any written policy of the Company; (ii) the repeated, willful, and persistent failure by Executive to reasonably and substantially perform Executive’s duties under this Agreement;
(iii) Executive’s willful misconduct or gross negligence which is injurious to the Company Group; or (iv) Executive’s indictment of or plea of guilty or nolo contendere to a felony or other serious crime involving moral
turpitude. No Cause shall exist unless the Board of Directors has provided Executive with written notice describing the particular circumstances giving rise to Cause, and has provided Executive the opportunity to cure, to the extent reasonably
susceptible to cure, such circumstances within thirty (30) days after receiving such notice. If the Executive so effects a cure to the satisfaction of the Board of Directors, the notice of Cause shall be deemed rescinded and of no force or
effect. If, within six (6) months following Executive’s termination of employment hereunder for other than Cause, it is determined in good faith by the Board of Directors following a reasonable and thorough investigation by the Company
that Executive’s employment could have been terminated for Cause pursuant to clauses (i), (iii) or (iv), the Board of Directors unanimously finds that the particular circumstances giving rise to Cause were or are not reasonably susceptible to
cure and the Company delivers written notice to Executive describing such circumstances giving rise to Cause, Executive’s employment shall be deemed to have been terminated for Cause retroactively to the date the events giving rise to Cause
occurred. 
 3.4 Termination by the Company without Cause, Resignation by Executive for Good Reason. If Executive’s
employment and the Term is terminated by the Company without Cause or Executive resigns for Good Reason during the Term, Executive shall be entitled, in addition to the Accrued Rights and subject to Executive’s continued compliance with this
Agreement and the Equity Agreements, and Executive’s execution, delivery and non-revocation of an effective release of all claims against the Company Group substantially in the form attached hereto as
Exhibit A the “Release”) within the sixty (60) day period following the date of the termination of Executive’s employment (the “Release Period”), to the payments and benefits set forth below. 

(a) Base Salary. Executive shall be entitled to receive for a period commencing on the Termination Date and ending on December 31,
2023 (the “Severance Period”), Executive’s then-current Base Salary, with such amounts to be paid in substantially equal installments in accordance with regular payroll practices, less applicable withholdings and taxes through
the Severance Period. 
 (b) Benefits. Executive shall be entitled to participate in the Company’s medical, dental and health
plans, at Executive’s cost but at the same rates as apply to active employees for a period commencing on the Termination Date and ending on the date that is eighteen (18) months following the Termination Date (the “COBRA Coverage
Period”), provided, that Executive is eligible and remains eligible for COBRA (as defined in Section 3.8) coverage. In the event that the Severance Period exceeds eighteen (18) months, then for each

  
 5 

 
month thereafter, commencing with the month immediately following the end of the COBRA Coverage Period and ending with the last month of the Severance Period, the Company shall pay Executive an
amount determined by the Company that reasonably equates to the Company’s cost of health insurance coverage for Executive that would otherwise be provided under COBRA at a level comparable to the health insurance coverage provided by the
Company immediately prior to Executive’s Termination Date. 
 (c) Annual Bonus. Executive shall be entitled to receive an amount
equal to Executive’s Target Bonus (i) for the fiscal year in which the Termination Date occurs and (ii) for each subsequent fiscal year, if any, during the Severance Period (the “Severance Bonus”), which Severance
Bonus shall be paid on the date that the Annual Bonus would otherwise have been paid had Executive remained employed with the Company, but, in any event, no earlier than January 1 and no later than March 15 of the year following the
performance year to which such Severance Bonus relates. 
 (d) Treatment of Outstanding Equity Awards. Notwithstanding anything in
the Equity Agreements, the DTZ Plan, the Company’s 2018 Omnibus Management Share and Cash Incentive Plan (the “Equity Plan”), those certain side letter agreements, dated as of June 8, 2018 and November 19, 2018, by
and among Parent, the Employer and Executive (the “Side Letters”) or any other agreement between Executive and the Company to the contrary, upon a termination pursuant to this Section 3.4, the outstanding
incentive equity held by Executive as of the Termination Date shall be treated in accordance with the terms set forth below. 
 (i)
Fiscal Year 2015 Options. As of the Termination Date, Executive shall be allowed to exercise any vested stock options granted to Executive in fiscal year 2015 for a period of up to ninety (90) days following the Termination Date. 

(ii) Fiscal Year 2018, 2019 and 2020 Time-Vesting RSUs. As of the Termination Date, all RSUs granted to Executive in fiscal years
2015, 2018, 2019 and 2020 that vest based solely on Executive’s continued employment and that remain outstanding and unvested as of the Termination Date, shall accelerate and fully vest as of the Termination Date and be satisfied by the Company
with a distribution of corresponding shares within thirty (30) days of the Termination Date. 
 (iii) Fiscal Year 2015
Performance-Vesting RSUs. As of the Termination Date, all RSUs granted to Executive in fiscal year 2015 that vest based on Executive’s continued employment and the Company’s achievement of specified performance metrics over a
performance period that remain outstanding and unvested as of the Termination Date, shall remain outstanding and eligible to vest if, and to the extent, the performance of the Company satisfies the applicable performance vesting requirements as of
the end of the applicable performance periods, as provided in the governing documents, as in effect from time to time. 
 (iv) Fiscal
Year 2018, 2019 and 2020 Performance-Vesting RSUs. As of the Termination Date, with respect to all RSUs granted to Executive in fiscal years 2018, 2019 and 2020 that vest based on Executive’s continued employment and the Company’s
achievement of specified performance metrics over a performance period that remain outstanding and 

  
 6 

 
unvested as of the Termination Date, Executive shall be deemed to have satisfied all continuous employment requirements through the applicable performance periods, and such performance-based
vesting RSUs shall remain outstanding and eligible to vest if, and to the extent, the performance of the Company satisfies the applicable performance vesting requirements as of the end of the applicable performance periods, as provided in the
applicable governing documents, as in effect from time to time. 
 (v) Fiscal Year 2021, 2022 and 2023 Time-Vesting RSUs. As of the
Termination Date, all RSUs granted to Executive in fiscal years 2021, 2022 and 2023 that vest based solely on Executive’s continued employment and that remain outstanding and unvested as of the Termination Date, shall accelerate and fully vest
as of the Termination Date and be satisfied by the Company with a distribution of corresponding shares within thirty (30) days of the Termination Date. 

(vi) Fiscal Year 2021, 2022 and 2023 Performance-Vesting RSUs. As of the Termination Date, with respect to any RSUs granted to
Executive in fiscal years 2021, 2022 and 2023 that vest based on Executive’s continued employment and the Company’s achievement of specified performance metrics over a performance period that remain outstanding and unvested as of the
Termination Date, Executive shall be deemed to have satisfied all continuous employment requirements through the applicable performance periods, and such performance-based vesting RSUs shall accelerate and fully vest as of the Termination Date based
upon levels of achievement reasonably determined by the Company as of the Termination Date, which such determination shall be based (i) upon the Company’s actual achievement of the specified performance metrics through the Termination
Date, (ii) upon target levels of performance for any remaining portion of the applicable performance period, and (iii) where a target performance metric includes a measurement for which clause (ii) cannot be applied, upon a reasonable
extrapolation of the Company’s performance through the performance period based upon the Company’s performance through the Termination Date. Such vested RSUs shall be satisfied by the Company with a distribution of corresponding shares
within thirty (30) days of the Termination Date. 
 If the Release Period spans two (2) calendar years, then payments that would otherwise have
been made prior to the end of the Release Period will be made, after the release becomes irrevocable, in lump sum on the first payroll date that occurs in the second calendar year. The Company agrees that any payments made to Executive under this
Section 3.4 will not be subject to mitigation. For purposes of this Agreement, “Good Reason” shall mean, without Executive’s consent: (i) any material diminution in Executive’s title, duties,
authority or responsibilities, including Executive no longer reporting only to the Board, (ii) any material reduction in Executive’s Base Salary or Target Bonus opportunity, (iii) a requirement by the Company that Executive relocate
more than fifty (50) miles from Los Angeles, California, or Dallas, Texas, (iv) a material breach by the Company of any of its other obligations contained in this Agreement or other material agreement between Executive and the Company; or
(v) the removal of Executive from the Board by the Company (other than for Cause) or the failure to re-elect Executive to serve on the Board; provided, that Good Reason shall not occur unless
Executive shall have (x) given a detailed written notice to the Company of any fact or circumstance believed by Executive to constitute Good Reason within ninety (90) days of the occurrence of such fact or circumstance, and (y) given
the Company thirty (30) days therefrom to cure such fact or 

  
 7 

 
circumstance and the Company shall have failed to so cure (it being understood that the Company cures the fact or circumstance giving rise to Good Reason, the notice of Good Reason shall be
deemed rescinded and of no force or effect). 
 3.5 Resignation by Executive without Good Reason. In the event Executive
resigns without Good Reason, Executive shall be entitled to receive the Accrued Rights; provided, that in the event Executive delivers to the Company a notice of an intent to resign upon the expiration of the Term no later than the 90th day prior to such expiration, subject to Executive’s execution, delivery and non-revocation of the Release within the Release Period and Executive’s
continued compliance with this Agreement and the Equity Agreements, Executive shall be entitled to continue to (i) receive for a period commencing on the Termination Date and ending on the date that the Company delivers to Executive a valid
waiver of its rights to enforce Executive’s obligations under Section 4.1(i), such period not to exceed eighteen (18) months (the “Enforcement Period”), Executive’s then- current Base Salary,
with such amounts to be paid in substantially equal installments in accordance with regular payroll practices, less applicable withholdings and taxes, (ii) participate in the Company’s medical, dental and health plans, at Executive’s
cost but at the same rates as apply to active employees for the Enforcement Period and (iii) notwithstanding anything in the Equity Agreements, the Side Letters, the DTZ Plan or any other agreement between Executive and the Company to the
contrary, as of the Termination Date, Executive shall be allowed to exercise any vested stock options granted to Executive in fiscal year 2015 for a period of up to ninety (90) days following the Termination Date. In the event Executive fails
to timely deliver an effective and non-revocable Release, or in the event Executive fails to comply with this Agreement or the Equity Agreements or his employment with the Company is deemed terminated by the
Company for Cause, the proviso in the immediately preceding sentence shall cease to have any force or effect and Executive shall repay to the Company, within thirty (30) days following written notice by the Company to Executive, any amounts
previously paid by the Company to Executive pursuant to clause (i) hereof. If the Release Period spans two (2) calendar years, then payments that would otherwise have been made prior to the end of the Release Period will be made, after the
release becomes irrevocable, in lump sum on the first payroll date that occurs in the second calendar year. The Company agrees that any payments made to Executive under this Section 3.5 will not be subject to mitigation.

 3.6 Change in Control Severance Benefits. In the event the Term and Executive’s employment terminates under this
Agreement as a result of the Company terminating Executive’s employment without Cause or Executive terminating his employment for Good Reason within twelve (12) months prior to or twenty-four (24) months following the consummation of
a Change in Control, notwithstanding anything to the contrary in Section 3.4 above, the Annual Bonus shall be an amount at least equal to Executive’s Target Bonus. 

3.7 Qualifying Resignation. Upon a Qualifying Resignation, (i) the outstanding RSUs held by Executive as of the date of
such Qualifying Resignation shall be treated in accordance with Sections 3.4(d)(ii)-(vi) of this Agreement, as applicable, as though the date of such Qualifying Resignation is the Termination Date and (ii) any vested and outstanding
stock options granted to Executive in fiscal year 2015 shall remain outstanding and exercisable for a period of up to ninety (90) days following the date upon which Executive is no longer providing services to the Company either as an employee
or as a member of the Board of Directors. Upon a 

  
 8 

 
Qualifying Resignation, Executive shall remain eligible, subject to the provisions of Section 2.4(a), to receive any remaining Equity Grants. With respect to the
remaining Equity Grants, if any, to be made to Executive in accordance with Section 2.4(a) following the date of a Qualifying Resignation, such Equity Grants shall be made in accordance with, and subject to the terms of,
Section 2.4(a), including, for the avoidance of doubt, the applicable vesting terms set forth in Section 2.4(a), as dependent on Executive’s capacity with the Company as of the grant date. For
purposes of this Agreement, a “Qualifying Resignation” shall occur on the earliest of: (x) (i) in the event that the Board of Directors determines that Executive will no longer serve as the Chief Executive Officer and, as a
result, Executive ceases to be employed by the Company and (ii) the Board of Directors determines in its sole discretion that as of the date Executive ceases to be employed (A) the Company has hired a new Chief Executive Officer and
(B) Executive has provided a transition plan and such assistance to the Company and such new Chief Executive Officer as the Board of Directors in its reasonable, good faith discretion believes is necessary and appropriate to ensure a smooth
transition of the role; (y) in the event that the Board of Directors and Executive mutually agree to maintain Executive as Executive Chairman of the Board of Directors following the Company’s appointment of a new Chief Executive Officer,
provided, that a Qualifying Resignation pursuant to clause (x) or (y) of this Section 3.7 shall occur no later than thirty (30) days following such event; or (z) automatically on December 31,
2023, provided, that Executive is employed with the Company as of such date. For the avoidance of doubt, a Qualifying Resignation shall only occur once. 

3.8 No Other Benefits Upon Termination. Except as provided in the applicable sub-section
of this Section 3, and except for any vested benefits under any plans of the Company and the continuation of health insurance benefits on the terms and to the extent required by Section 4980B of the Code and
Section 601 of the Employee Retirement Income Security Act of 1974, as amended (which provisions are commonly known as “COBRA”), the Company shall have no additional obligations upon the termination of Executive’s
employment with the Company and the Term. 
 3.9 Cooperation with Company after Termination of Employment. Following
termination of Executive’s employment and the Term for any reason, Executive shall reasonably cooperate with the Company in all matters relating to the winding up of his pending work on behalf of the Company including, but not limited to, any
litigation in which the Company is involved and the orderly transfer of any such pending work to other employees of the Company as may be designated by the Company. The Company’s request for “reasonable cooperation” shall take into
consideration Executive’s personal and business commitments and the amount of notice provided to Executive. The Company shall reimburse Executive for any reasonable
out-of-pocket expenses he incurs in performing any work on behalf of the Company following the Termination Date. 

4. NON-SOLICITATION & NON-COMPETITION 

4.1 Non-Compete; Non-Solicit. Executive agrees
that he shall not, directly or indirectly, (i) during the Term and for the eighteen (18) month period following the Termination Date, become an employee, director, or independent contractor, stockholder or other owner (other than a holder
of less than 1% of the outstanding voting shares of any publicly held company) of, or a consultant to, or perform any services for, any Person who derives or 

  
 9 

 
reasonably expects to derive, based upon a preponderance of facts and circumstances, more than 20% of its revenue from one or more Commercial Real Estate Services (a “Competing
Business”), or (ii) during the Term and for the twenty-four (24) month period following the Termination Date, solicit or hire or attempt to solicit or hire, as applicable, (A) any customer or supplier of the Company Group in
connection with a Competing Business or to terminate or alter in a manner adverse to the Company Group such customer’s or supplier’s relationship with the Company Group, or (B) any employee or individual who was an employee within the
six (6) month period immediately prior thereto to terminate or otherwise alter his or her employment with the Company Group. “Commercial Real Estate Services” means those services of the type provided by the Company Group,
including but not limited to the leasing, sales, development, property management, facilities management, consulting, mortgage origination and servicing, valuation and appraisal services, real estate related structured finance and debt and
investment management delivered to occupiers, owners, lenders and investors in office, retail, industrial, multi-family and other commercial real estate assets. For purposes of this Agreement, “Person” shall mean any individual,
partnership, corporation, limited liability company, unincorporated organization, trust or joint venture, or a governmental agency or political subdivision thereof. 

4.2 Non-Disparagement. During the Term and thereafter, Executive agrees that he will
not, at any time, make or encourage others to make, directly or indirectly, any oral or written statements that are disparaging or defamatory of the Company Group, its products, services, customers or suppliers, or any of its present or former
officers, directors or employees. The Company shall instruct those employees with authority to speak on the matter not to make negative, derogatory or disparaging comments regarding the Executive. 

4.3 Confidential Information. Executive acknowledges and agrees that all information regarding the Company Group or the activity
of any member of the Company Group that is not generally known to persons not employed or retained (as employees or as independent contractors or agents) by the Company Group, including without limitation information about the customers, business
connections, customer lists, procedures, operations, trade secrets, techniques and other aspects of and information about the business of the Company Group (the “Confidential Information”) is established at great expense and
protected as confidential information and provides the Company Group with a substantial competitive advantage in conducting its business. Confidential Information shall not mean information (i) which has been voluntarily disclosed to the public
by the Company, except where such public disclosure has been made by Executive without authorization from the Company, (ii) which has been independently developed and disclosed by others, (iii) in Executive’s possession or known to
Executive prior to his consulting for the Company and not disclosed to Executive by the Company or any affiliate of the Company (whether or not an affiliate of the Company at the time of such disclosure), including but not limited to information
that is located on Executive’s rolodex (whether paper or electronic), or (iv) which has otherwise entered the public domain through lawful means. Executive further acknowledges and agrees that by virtue of his employment with the Company,
he has had access to and will have access to, and has been entrusted with and will be entrusted with Confidential Information, and that the Company Group would suffer great loss and injury if Executive would disclose this information or use it in a
manner not specifically authorized by the Company. Therefore, Executive agrees that during the Term and at all times thereafter, he will not, directly or indirectly, either individually or as an employee, agent, partner, shareholder, owner, trustee,
beneficiary, co-venturer distributor, 

  
 10 

 
consultant or in any other capacity, use or disclose or cause to be used or disclosed any Confidential Information, unless and to the extent that any such information becomes generally known to
and available for use by the public other than as a result of Executive’s acts or omissions. Executive shall deliver to the Company at the termination of his employment and the Term, or at any other time the Company may request, all memoranda,
notes, plans, records, reports, computer tapes, printouts and software and other documents and data (and copies thereof) relating to the Confidential Information, or the business of the Company which he may then possess or have under his control. In
addition, Executive agrees that, notwithstanding the foregoing, to the extent Executive is compelled to disclose Confidential Information by lawful service of process, subpoena, court order, or otherwise compelled to do by law, Executive shall, to
the extent legally permitted, provide the Company with a copy of the document(s) seeking disclosures of such information promptly upon receipt of such document(s) and prior to Executive’s disclosure of any such information, so that the Company
may take such action as it deems to be necessary or appropriate in relation to such subpoena or request and Executive may not disclose any such information until the Company has had the opportunity to take such action. 

4.4 Intellectual Property 

(a) If Executive creates, invents, designs, develops, contributes to or improves any works of authorship, inventions, intellectual property,
materials, documents or other work product (including, without limitation, research, reports, software, databases, systems, applications, presentations, textual works, content or audiovisual materials) (“Works”), either alone or
with third parties, at any time during Executive’s employment with any member of the Company Group and within the scope of such employment and/or with the use of any the Company Group resources (“Company Works”), Executive
shall promptly and fully disclose same to the Company and hereby irrevocably assigns, transfers and conveys, to the maximum extent permitted by applicable law, all rights and intellectual property rights therein (including rights under patent,
industrial property, copyright, trademark, trade secret, unfair competition and related laws) to the Company to the extent ownership of any such rights does not vest originally in the Company. 

(b) Executive shall take all requested actions and execute all requested documents (including any licenses or assignments required by a
government contract) at the Company’s expense (but without further remuneration) to assist the Company in validating, maintaining, protecting, enforcing, perfecting, recording, patenting or registering any of the Company’s rights in the
Company Works. If the Company is unable for any other reason to secure Executive’s signature on any document for this purpose, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as
Executive’s agent and attorney in fact, to act for and in Executive’s behalf and stead to execute any documents and to do all other lawfully permitted acts in connection with the foregoing. 

(c) Executive shall not improperly use for the benefit of, bring to any premises of, divulge, disclose, communicate, reveal, transfer or
provide access to, or share with, the Company Group, any confidential, proprietary or non-public information or intellectual property relating to a former employer or other third party without the prior
written permission of such third party. Executive shall comply with all relevant policies and guidelines of the Company, including, without limitation, policies and guidelines regarding the protection of

  
 11 

 
confidential information and intellectual property and potential conflicts of interest. Executive acknowledges that the Company may amend any such policies and guidelines from time to time, and
that Executive remains at all times bound by their most current version. 
 4.5 Reasonable Limitation and Severability; Injunctive
Relief. The parties agree that the above restrictions are (i) reasonable given Executive’s role with the Company, and are necessary to protect the interests of the Company Group and (ii) completely severable and independent
agreements supported by good and valuable consideration and, as such, shall survive the termination of this Agreement for any reason whatsoever. The parties further agree that any invalidity or unenforceability of any one or more of such
restrictions on competition shall not render invalid or unenforceable any remaining restrictions on competition. Additionally, should a court of competent jurisdiction determine that the scope of any provision of this
Section 4 is too broad to be enforced as written, the parties hereby authorize the court to reform the provision to such narrower scope as it determines to be reasonable and enforceable and the parties intend that the
affected provision be enforced as so amended. Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened breach may be inadequate and the Company may suffer significant harm and irreparable damages as a
result of a breach or threatened breach. In recognition of this fact, Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, may be entitled to cease making any payments or
providing any benefit otherwise required by this Agreement and seek to obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be
available. The remedies under this Agreement are without prejudice to the Company’s right to seek any other remedy to which it may be entitled at law or in equity. 

4.6 Certain Disclosures. Notwithstanding anything herein or in any other agreement with or policy (including without limitation
any code of conduct or employee manual) of the Company, nothing herein or therein is intended to or shall: (i) prohibit Executive from making reports of possible violations of federal law or regulation (even if the participated in such
violations) to, and cooperating with, any governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002 or
of any other whistleblower protection provisions of state or federal law or regulation; (ii) require notification to or prior approval by the Company of any such reporting or cooperation; or (iii) result in a waiver or other limitation of
Executive’s rights and remedies as a whistleblower, including to a monetary award. Notwithstanding the foregoing, Executive is not authorized (and the above should not be read as permitting Executive) to disclose communications with counsel
that were made for the purpose of receiving legal advice or that contain legal advice or that are protected by the attorney work product or similar privilege. Furthermore, Executive will not be held criminally or civilly liable under any federal or
state trade secret law for the disclosure of a trade secret that is made (1) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, in each case, solely for the purpose of reporting or
investigating a suspected violation of law or (2) in a complaint or other document filed in a lawsuit or proceeding, if such filings are made under seal. 

  
 12 

 5. GENERAL PROVISIONS 

5.1 Assignment; Successors. This Agreement is binding on and is for the benefit of the parties hereto and their respective
successors, assigns, heirs, executors, administrators and other legal representatives. Neither this Agreement nor any right or obligation hereunder may be assigned by Executive. The Company shall require any successor (whether direct or indirect, by
purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume this Agreement in the same manner and to the same extent that the Company would have been required to perform it if no
such succession had taken place. As used in the Agreement, “the Company” shall mean both the Company as defined above and any such successor that assumes this Agreement, by operation of law or otherwise. 

5.2 Notice. For the purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in
writing and shall be deemed to have been duly given when delivered or mailed by certified or registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below: 

 

			
	To the Company:	  	Cushman & Wakefield Global, Inc.
		  	225 West Wacker Drive, Suite 3000
		  	Chicago, IL 60606
		  	Attention: General Counsel

 If to the Executive, to the most recent address shown on the records of the Company. 

5.3 Amendment and Waiver. No provision of this Agreement may be amended or waived unless such amendment or waiver is in writing
and signed by each of the parties hereto. 
 5.4 Non-Waiver of Breach. No failure by
either party to declare a default due to any breach of any obligation under this Agreement by the other, nor failure by either party to act quickly with regard thereto, shall be considered to be a waiver of any such obligation, or of any future
breach. 
 5.5 Severability. In the event that any provision or portion of this Agreement, shall be determined to be invalid
or unenforceable for any reason, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect. 

5.6 Governing Law. To the extent not preempted by federal law, the validity and effect of this Agreement and the rights and
obligations of the parties hereto shall be construed and determined in accordance with the law of Illinois. The parties irrevocably consent to the jurisdiction of, and venue in, the courts in the state of Illinois, with respect to any matters
pertaining to, or arising from, this Agreement. 
 5.7 Waiver of Jury Trial. The parties each hereby waives, to the fullest
extent permitted by law, any right to trial by jury of any claim, demand, action, cause of action (i) arising under this Agreement or (ii) in any way connected with or related or incidental to the dealings of the parties hereto in respect
of this Agreement whether now existing or hereafter arising, and whether in contract, tort, equity or otherwise. The parties to this Agreement each hereby agrees and consents that any such claim, demand, action or cause of action shall be decided by
court trial without a jury and that the parties may file an original counterpart of a copy of this Agreement with any court as written evidence of the consent of the parties to the waiver of their right to trial by jury. 

  
 13 

 5.8 Entire Agreement. This Agreement contains all of the terms agreed upon by
the Company and Executive with respect to the subject matter hereof and supersedes all prior agreements, arrangements and communications between the parties dealing with such subject matter, whether oral or written, including without limitation the
Original Employment Agreement and, to the extent provided herein, those certain provisions of the Side Letters. In the event of a conflict between this Agreement and any other agreement between the Company and Executive, this Agreement shall
control. 
 5.9 Headings. Numbers and titles to Sections hereof are for information purposes only and, where inconsistent with
the text, are to be disregarded. 
 5.10 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original, but all of which when taken together, shall be and constitute one and the same instrument. 
 5.11
Taxes. 
 (a) The Company may withhold from any payment hereunder such state, federal or local income, employment or other taxes and
other legally mandated withholdings as it reasonably deems appropriate. The Company makes no representation about the tax treatment or impact of any payment(s) hereunder. 

(b) The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Code, as amended
(“Section 409A”), to the extent subject thereto, or are otherwise exempt therefrom, and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance
therewith or exempt therefrom. Notwithstanding anything herein to the contrary: (i) if at the time of Executive’s termination of employment with the Company, Executive is a “specified employee” as defined in Section 409A and
the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A, then the Company will
defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six (6) months following Executive’s
termination of employment with the Company (or the earliest date as is permitted under Section 409A); (ii) if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional
tax under Section 409A, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A, or otherwise such payment or other benefits shall be restructured, to the extent
possible, in a manner determined by the Company that does not cause such an accelerated or additional tax; (iii) to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A, Executive shall not be
considered to have terminated employment with the Company for purposes of this Agreement and no payment shall be due to Executive under this Agreement until Executive would be considered to have incurred a “separation from service” from
the Company within the 

  
 14 

 
meaning of Section 409A; and (iv) each amount to be paid or benefit to be provided to Executive pursuant to this Agreement, which constitute deferred compensation subject to
Section 409A, shall be construed as a separate identified payment for purposes of Section 409A. To the extent required to avoid an accelerated or additional tax under Section 409A, amounts reimbursable to Executive under this
Agreement shall be paid to Executive on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits
provided to Executive) during any one year may not affect amounts reimbursable or provided in any subsequent year. Neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to
Section 409A. 
 5.12 Clawback. Notwithstanding anything in this Agreement to the contrary, Executive acknowledges that
the Company may be entitled according to the parties’ agreement, or as required by law, the Company’s written policy as may be in effect from time to time (the “Clawback Policy”) or the requirements of an exchange on which
the Company’s or its parent’s shares are listed for trading, to recoup compensation paid to Executive pursuant to this Agreement or otherwise, and Executive agrees to comply with any such request or demand for recoupment by the Company.

 5.13 Return of Property. Upon termination of Executive’s employment with the Company for any reason, Executive shall
immediately destroy, delete, or return to the Company, at the Company’s option, all originals and copies in any form or medium (including memoranda, books, papers, plans, computer files, letters and other data) in Executive’s possession or
control that contain Confidential Information or otherwise relate to the business of the Company Group, and cooperate with the Company regarding the delivery or destruction of any other Confidential Information of which Executive is or becomes
aware, and shall otherwise return to the Company all property of the Company Group. 
 5.14 No Conflict. Executive represents
and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive does not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or
decree to which Executive is a party or by which he is bound, and (ii) Executive is not a party to or bound by an employment agreement, non-compete agreement,
non-solicit agreement or confidentiality agreement with any other Person which would interfere in any material respect with the performance of his duties hereunder. 

5.15 Survival. Except as otherwise expressly provided in this Agreement, all covenants, representations and warranties, express
or implied, in addition to the provisions of Sections 4 and 5 of this Agreement, shall survive the termination of this Agreement. 

5.16 Representation. Executive acknowledges and agrees that Executive was represented by counsel in connection with the
negotiation of this Agreement, namely Proskauer Rose LLP. Executive acknowledges and agrees that the Company’s principal place of business and headquarters are located in Chicago, Illinois, and even though Executive may not be physically
located in the State of Illinois, at all times for the performance of all of Executive’s duties and responsibilities under this Agreement, Executive will be required to travel routinely to Illinois on business on behalf of the Company, and
Executive, through his employment and duties and responsibilities under this Agreement, is effectively providing services to the 

  
 15 

 
Company within the State of Illinois. Executive further acknowledges and agrees that pursuant to Section 925 of the California Labor Code, (i) Executive has waived the application of
California law to this Agreement and any proceeding, (ii) Executive has waived any right to have any proceeding adjudicated in California, and (iii) Executive acknowledges and agrees that any proceeding or claim shall not be deemed to be a
controversy arising in California. 
 IN WITNESS WHEREOF, the parties hereto have caused this Employment Agreement to be duly executed on
the date and year first written above. 
  

							
	CUSHMAN & WAKEFIELD GLOBAL, INC.	 		 	EXECUTIVE
				
	By:	 	 /s/ Brett Soloway
	 		 	 /s/ Brett White

	Name:	 	Brett Soloway	 		 	Brett White
	Title:	 	Director	 		 	

  

			
	
	CUSHMAN & WAKEFIELD PLC
		
	By:	 	 /s/ Tim Dattels

	Name:	 	Tim Dattels
	Title:	 	Lead Director

  
 16 

 EXHIBIT A 

RELEASE AGREEMENT 
 This
Release Agreement (“Release”) is hereby made among [●] (“Executive”), Cushman & Wakefield Global, Inc.1 (the “Employer”) and
Cushman & Wakefield plc (together with the Employer, the “Company”). 
 I. RECITALS 

WHEREAS, Executive and the Company have entered into an Amended and Restated Employment Agreement dated August 27, 2020 (the “Employment
Agreement”), pursuant to which Executive may be entitled to receive severance and certain benefits pursuant to Sections 3.4, 3.5, 3.6 or 3.7 of the Employment Agreement, as applicable (the “Severance
Benefits”) in the event of certain specified terminations of employment, subject to and conditioned upon his execution of a general release. 

WHEREAS, Executive and the Company desire to enter into this Release, in satisfaction of such condition under the Employment Agreement. 

II. TERMS AND CONDITIONS 
 NOW,
THEREFORE, in consideration of the mutual covenants and other good and valuable consideration contained herein, the parties hereby agree as follows: 

1. Separation. Executive’s employment with the Company and all of its subsidiaries and Affiliates ended
effective            . Executive has the right to receive Severance Benefits subject to his execution of this Release, as provided under the Employment Agreement. 

2. General Release and Covenant Not to Sue. Executive hereby releases, remises and acquits the Company and/or its direct or indirect parents,
subsidiaries, affiliates and related entities, and all of their predecessors, successors, assigns, trustees and current or former officers, directors, shareholders, members, partners, agents, employees, consultants, independent contractors,
attorneys and advisers (collectively, the “Releasees”), jointly and severally, from any and all claims, known or unknown, which Executive or Executive’s heirs, successors or assigns have or may have against any of the Releasees
arising on or prior to the date of execution of this Agreement and any and all liability which any of the Releasees may have to Executive, heirs, successors and assigns whether denominated claims, demands, causes of action, obligations, damages or
liabilities arising from any and all bases, however, denominated, including but not limited to, the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act of 1990, the Family and Medical Leave Act of
1993, Title VII of the United States Civil Rights Act of 1964, 42 U.S.C. § 1981, any other federal, state or local law and any workers’ compensation or disability claims under any such laws or claims under any contract. This release
relates to claims by reason of any matter, cause or thing occurring, done or omitted to be done from the beginning of the world until the date of the execution hereof. 
  

 

	1 	 To be updated to reflect change to employing entity as of time of termination, if any.

  
 A-1 

 
Executive further agrees that Executive will not file or permit to be filed on Executive’s behalf any such claim. Notwithstanding the preceding sentence or any other provision of this
Agreement, this release is not intended to interfere with Executive’s right to file a charge with the Equal Employment Opportunity Commission (the “EEOC”) in connection with any claim he believes he may have against the
Company. However, by executing this Agreement, Executive hereby waives the right to recover in any proceeding Executive may bring before the EEOC or any state or local human rights commission or in any proceeding brought by the EEOC or any state or
local human rights commission on Executive’s behalf. In addition, this release is not intended to interfere with Executive’s right to challenge that his waiver of any and all ADEA claims pursuant to this Agreement is a knowing and
voluntary waiver, notwithstanding Executive’s specific representation that he has entered into this Agreement knowingly and voluntarily. This release is for any relief, no matter how denominated, including, but not limited to, injunctive
relief, wages, back pay, front pay, compensatory damages, or punitive damages. This release shall not apply to any obligation of the Company pursuant to this Agreement, any rights in the nature of indemnification which Executive may have with
respect to claims against Executive relating to or arising out of his employment with the Company, or any vested benefit to which Executive is entitled under any tax qualified pension plan of the Company, COBRA continuation coverage benefits or any
other similar benefits required to be provided by statute. 
 3. Voluntary Agreement. Executive understands and acknowledges the significance and
consequences of this Release, that it is voluntary, that it has not been given as a result of any coercion, and expressly confirms that it is to be given full force and effect according to all of its terms, including those relating to unknown
Claims. Executive was hereby advised of Executive’s right to seek the advice of an attorney prior to signing this Release. Executive and Company each acknowledge that they have signed this Release only after full reflection and analysis, that
they understand it and are entering into it voluntarily. 
 4. Period for Consideration of Agreement and Other Matters. Executive acknowledges that,
before signing this Release, Executive was given a period of at least twenty-one (21) days to consider this Release. Executive also understands that he has the right to change his mind and cancel this
Release by providing written notice to the Company no later than seven (7) days following the date that Executive has signed it. This Release will not be effective until the end of this seven (7) day period. Executive acknowledges that
Executive was advised to consult with legal counsel prior to executing a copy of this Release. 
 5.
Non-Admission. Executive and the Company agree that this Agreement does not constitute and shall not be construed, interpreted, or treated in any respect as an admission of any liability or wrongdoing
by Executive or the Release Parties. Executive and the Company further agree that this Release shall not be admissible in any proceeding without Executive’s and the Company’s written consent, except for a proceeding instituted by Executive
or the Company challenging the validity of this Release, a proceeding by Executive or the Company alleging a breach of this Release or the Employment Agreement, any proceeding in which a defense is asserted based on any provisions of this Release,
or as otherwise required by law. 
 6. Choice of Law, Interpretation and Severability. Executive and the Company agree that this Agreement shall be
governed by Illinois law and may be modified by the Company, from time to time, to reflect any applicable changes in Illinois law. Executive and the Company agree 

  
 A-2 

 
that this Agreement shall not be construed against any party on account of authorship and, if a court finds any part of this Agreement to be illegal or invalid, the illegal or invalid portion of
the Agreement shall be severed and the rest of the Agreement will be enforceable. Moreover, if any one or more of the provisions contained in this Agreement is held to be excessively broad as to duration, scope, activity or subject, such provisions
will be construed by limiting and reducing them so as to be enforceable to the maximum extent compatible with applicable law. 
 7. Execution. This
Agreement may be executed in two or more facsimiled counterparts, each of which shall be equivalent to an original, but which collectively shall constitute one Agreement. 

8. Entire Agreement. Except as otherwise set forth herein, the terms contained in this Agreement constitute the entire agreement between the parties
with respect to the subject matter hereof and supersede all prior agreements relating thereto whether written or oral. 
 9. Certain Disclosures.
Notwithstanding anything herein or in any other agreement with or policy (including without limitation any code of conduct or employee manual) of the Company or its affiliates, nothing herein or therein is intended to or shall: (i) prohibit
Executive from making reports of possible violations of federal law or regulation (even if Executive participated in such violations) to, and cooperating with, any governmental agency or entity in accordance with the provisions of and rules
promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002 or of any other whistleblower protection provisions of state or federal law or regulation; (ii) require notification
to or prior approval by the Company of any such reporting or cooperation; or (iii) result in a waiver or other limitation of Executive’s rights and remedies as a whistleblower, including to a monetary award. Notwithstanding the foregoing,
Executive is not authorized (and the above should not be read as permitting Executive) to disclose communications with counsel that were made for the purpose of receiving legal advice or that contain legal advice or that are protected by the
attorney work product or similar privilege. Furthermore, Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (1) in confidence to a federal, state
or local government official, either directly or indirectly, or to an attorney, in each case, solely for the purpose of reporting or investigating a suspected violation of law or (2) in a complaint or other document filed in a lawsuit or
proceeding, if such filings are made under seal. 
 [Signature Page Follows] 

  
 A-3 

									
	AGREED TO AND ACCEPTED BY:	 		 	
				
	Executive	 		 		 	Cushman & Wakefield Global, Inc.2
			
	  
	 		 	  

					
	Date:	 	  
	 		 	Name:	 	  

		 		 		 	Title:	 	  

				
		 		 		 	Cushman & Wakefield plc
					
		 		 		 	By:	 	  

		 		 		 	Name:	 	Tim Dattels
		 		 		 	Title:	 	Lead Director

  
  

	2 	 To be updated to reflect change to employing entity as of time of termination, if any. 

  
 A-4Document

        

Exhibit 10.1
MARVELL TECHNOLOGY GROUP LTD.
CHANGE IN CONTROL SEVERANCE PLAN
AND SUMMARY PLAN DESCRIPTION
Updated June 25, 2020
1.Introduction.  The purpose of this Marvell Technology Group Ltd. Change in Control Severance Plan (the “Plan”) is to provide assurances of specified benefits to certain employees of the Company whose employment is subject to being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described in the Plan.  This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA.  This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan.
2.Important Terms.  The following words and phrases, when the initial letter of the term is capitalized, will have the meanings set forth in this Section 2, unless a different meaning is plainly required by the context:
2.1 “Administrator” means the Company, acting through the Compensation Committee or another duly constituted committee of members of the Board, or any person to whom the Administrator has delegated any authority or responsibility with respect to the Plan pursuant to Section 12, but only to the extent of such delegation.
2.2 “Board” means the Board of Directors of the Company.
2.3 “Cause” shall mean any of the following reasons:
(a) an act of material dishonesty made by the Participant in connection with the Participant’s job responsibilities as an employee;
(b) the Participant’s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or moral turpitude;
(c) the Participant’s gross misconduct;
(d) the Participant’s willful unauthorized use or disclosure of any proprietary information or trade secrets of the Company (or a parent or subsidiary employing the Participant) ;
(e) the Participant’s willful breach of any obligations under any written agreement with the Company (or a parent or subsidiary employing the Participant) that is not cured within 10 days after Participant’s receipt of written notice from the Company or Marvell specifying the breach;
(f) the Participant’s willful refusal to cooperate in good faith with a governmental or internal investigation of the Company (or a parent or subsidiary employing the Participant) or their directors, officers or employees, if the Company has requested the Participant’s cooperation; or
1

(g) the Participant’s willful failure to substantially perform the Participant’s employment duties with the Company (or a parent or subsidiary employing the Participant), other than as a result of incapacity due to physical or mental illness; provided that the action or conduct described in this clause (g)  will constitute “Cause” only if such failure continues after the Company’s Board of Directors or Chairman of the Board has provided Participant with a written demand for substantial performance setting forth in detail the specific respects in which the Company believes Participant has willfully failed to substantially perform his duties thereof and Participant has been provided a reasonable opportunity (to be not less than 20 days) to cure the same.
With respect to clauses (a)-(f), if the condition triggering Cause is curable in the good faith judgment of the Administrator, Participant will be provided written notice which specifically sets forth the factual basis for the Company’s belief that Cause has occurred, and a termination for Cause will not occur until Participant has been provided 10 business days after Participant’s receipt of the written notice to cure the condition.
2.4  “Change in Control” means:
(a) a merger or consolidation in which the holders of stock possessing a majority of the voting power in the surviving entity (or a parent of the surviving entity) did not own a majority of the common stock immediately before the transaction;
(b) the sale of all or substantially all of the Company’s assets to any other person or entity (other than a subsidiary);
(c) the liquidation or dissolution of the Company; or
(d) the direct or indirect acquisition by any person or related group of persons of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than 50% of the total combined voting power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s shareholders that the Board does not recommend that the shareholders accept.
Notwithstanding the preceding, no transaction will be a Change in Control under this definition unless it is also a “change in control” within the meaning of Treasury Regulation Section 1.409A-3(i)(5) if it would cause a payment or benefit under the Plan that is subject to Section 409A to fail to meet the requirements of Section 409A.
2.5 “Change in Control Period” means the time period beginning upon the date 3 months prior to a Change in Control and ending on the date that is 24 months following the Change in Control.
2.6 “Code” means the Internal Revenue Code of 1986, as amended.
2.7 “Company” means Marvell Technology Group Ltd., a Bermuda corporation, and any successor that assumes the obligations of the Company under the Plan, by way of merger, acquisition, consolidation or other transaction.
2

2.8 “Designated Participant” means each of the Chief Executive Officer, Chief Financial Officer and Chief Legal Officer (or General Counsel if there is no Chief Legal Officer) of the Company as of immediately prior to a Change in Control.
2.9 “Disability” will mean that a Participant has been unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months. Alternatively, a Participant will be deemed disabled if determined to be totally disabled by the Social Security Administration.
2.10 “ECC” means the Executive Compensation Committee of the Board.
2.11 “Effective Date” means the date the Plan is adopted by the Board or the ECC.
2.12 “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.   
2.13 “Equity Awards” means a Participant’s outstanding stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance stock units and any other Company equity compensation awards.
2.14 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
2.15 “Good Reason” means a Participant’s voluntary resignation as an employee of the Company within 30 days following the expiration of any Cure Period after one of the following conditions has come into existence without his or her consent:

(a) a change in the Participant’s position within the Company (or a parent or subsidiary employing the Participant) that materially reduces the Participant’s level of duties, authority or responsibilities; provided, however, that (i) with respect to a Participant other than Designated Participants, (x) a change in the Participant’s position or title following a Change in Control shall not constitute Good Reason so long as the Participant retains substantially the same duties and responsibilities of a division, subsidiary or business unit that constitutes or includes a significant portion of the business of the Company following the Change in Control (the “Post-Closing Marvell Business”); or (y) if Participant continues to report to the functional head of the Post-Closing Marvell Business (regardless of whether Participant reports to the chief executive officer of the parent or acquirer of the Post-Closing Marvell Business) and retains substantially the same duties and responsibilities with respect to the Post-Closing Marvell Business, then there shall be no Good Reason under this clause (a); and (ii) with respect to a Designated Participant, if there is a change in Participant’s role after which Participant does not have the role as chief executive officer, chief financial officer or chief legal officer, as applicable, with respect to a parent entity whose stock is publicly-traded, then such a change shall affirmatively constitute Good Reason; 
(b) a reduction of 10% or greater in the Participant’s level of annual base salary  or incentive compensation eligibility; or
3

(c) the Company requires (i) the Participant to relocate the principal place of performance of the Participant’s duties to a location more than 30 miles from the Participant’s principal place of performance at the time of consummation of the Change in Control and (ii) the relocation results in a greater commute by the Participant.
The Participant’s resignation will not constitute a resignation for “Good Reason” unless the Participant first provides the Company (or a parent or subsidiary employing the Participant) with written notice of the acts or omissions constituting the grounds for “Good Reason” within 90 days of the initial existence of the grounds for “Good Reason” and provides the Company with 30 days following the date of such notice to cure the condition constituting “Good Reason” (the “Cure Period”).  
The determination of whether Good Reason exists, including the determination of the cure of any condition constituting Good Reason, shall be made in all cases by the Administrator in accordance with authorities and deference afforded to the Administrator under Section 12 of the Plan.
2.16 “Involuntary Termination” means a termination of employment of a Participant under the circumstances described in Section 5.  
2.17 “Participant” means an employee of the Company or of any parent or subsidiary of the Company who (a) has been designated by the Administrator to participate in the Plan and (b) has timely and properly executed and delivered a Participation Agreement to the Company.
2.18 “Participation Agreement” means the individual agreement (as will be provided in separate cover as Appendix A) provided by the Administrator to a Participant under the Plan, which has been signed and accepted by the Participant.
2.19 “Plan” means the Marvell Technology Group Ltd. Change in Control Severance Plan, as set forth in this document, and as hereafter amended from time to time.
2.20 “Section 409A Limit” means 2 times the lesser of: (i) the Participant’s annualized compensation based upon the annual rate of pay paid to the Participant during the Participant’s taxable year preceding the Participant’s taxable year of the Participant’s termination of employment as determined under, and with such adjustments as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Participant’s employment is terminated.
2.21 “Severance Benefits” means the compensation and other benefits that the Participant will be provided in the circumstances described in Section 5.
4

3.Treatment of Equity Awards that are Not Assumed or Substituted for in the Event of a Change in Control.  In the event of a Change in Control where the successor corporation does not assume a Participant’s Equity Awards or substitute Equity Awards for substantially similar awards with the same or more favorable vesting schedule and other terms as the Participant’s Equity Awards, then the Participant’s Equity Awards will vest in full and the Participant will have the right to exercise all of his or her outstanding stock options and stock appreciation rights, including shares as to which such Equity Awards would not otherwise be vested or exercisable, all restrictions on his or her restricted stock and restricted stock units will lapse, and, with respect to his or her Equity Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and conditions met; provided however, that (A) if there is no “target” level, then the number that will vest shall be 100% of the maximum amount that could vest with respect to that relevant measurement period(s); and (B) if the performance period has been completed and the actual performance achieved is greater than the target level, then the number that will vest shall be 100% of the amount that would vest based on that actual performance achievement level with respect to that relevant measurement period; and (C) if the performance criteria is a Total Shareholder Return (“TSR”) or other measure based on the value of the Company’s stock, the amount that will vest will be calculated as if the measurement period ended on the date of the Change in Control (and including the final closing price of the Company’s stock on such date).   In addition, if any of the Participant’s stock options or stock appreciation rights are not assumed or substituted for in the Change in Control, the Company will notify the Participant in writing or electronically that such stock options or stock appreciation rights will be exercisable for a period of time determined by the Board in its sole discretion, and the stock options or stock appreciation rights will terminate upon the expiration of such period.  
4.Eligibility for Severance Benefits.  An individual is eligible for Severance Benefits under the Plan, as described in Section 5, only if he or she experiences an Involuntary Termination.  
5.Involuntary Termination During the Change in Control Period.  If, during the Change in Control Period, (i) a Participant terminates his or her employment with the Company (or any parent or subsidiary of the Company) for Good Reason, or (ii) the Company (or any parent or subsidiary of the Company) terminates the Participant’s employment for a reason other than Cause or the Participant’s death or Disability (in either case, an “Involuntary Termination”), then, in each case, subject to the Participant’s compliance with Section 7, the Participant will receive the following Severance Benefits:
5.1 Cash Severance Benefits.  A lump-sum payment of cash severance equal to the amount set forth in the Participant’s Participation Agreement;
5.2 Equity Award Vesting Acceleration Benefit.  The Participant’s Equity Awards will accelerate and vest to the amount set forth in the Participant’s Participation Agreement; and
5

5.3 Continued Medical Benefits.  If the Participant, and any spouse and/or dependents of the Participant (“Family Members”) has coverage on the date of the Participant’s Involuntary Termination under a group health plan sponsored by the Company, the Company will reimburse the Participant the total applicable premium cost for continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) during the period of time following the Participant’s employment termination, as set forth in the Participant’s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and his Family Members. However, if the Company determines in its sole discretion that it cannot provide the COBRA reimbursement benefits without potentially violating applicable laws (including, without limitation, Section 2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), the Company will in lieu thereof provide to the Participant a monthly payment in an amount equal to the monthly COBRA premium (on an after-tax basis) that the Participant would be required to pay to continue the group health coverage in effect on the date of the Participant’s termination of employment (which amount will be based on the premium for the first month of COBRA coverage) for the period of time set forth in the Participant’s Participation Agreement following the termination, which payments will be made regardless of whether the Participant elects COBRA continuation coverage.
6.Limitation on Payments.  In the event that the severance and other benefits provided for in this Plan or otherwise (“280G Payments”) payable to a Participant (i) constitute “parachute payments” within the meaning of Section 280G of the Code, and (ii) but for this Section 6, would be subject to the excise tax imposed by Section 4999 of the Code, then the 280G Payments will be either:
(a)delivered in full, or

(b)delivered as to such lesser extent which would result in no portion of such benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by the Participant on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. If a reduction in severance and other benefits constituting “parachute payments” is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order: (i) cancellation of awards granted “contingent on a change in ownership or control” (within the meaning of Code Section 280G); (ii) a pro rata reduction of (A) cash payments that are subject to Section 409A as deferred compensation and (B) cash payments not subject to Section 409A of the Code; (iii) a pro rata reduction of (A) employee benefits that are subject to Section 409A as deferred compensation and (B) employee benefits not subject to Section 409A; and (iv) a pro rata cancellation of (A) accelerated vesting equity awards that are subject to Section 409A as deferred compensation and (B) equity awards not subject to Section 409A. In the event that acceleration of vesting of equity awards is to be cancelled, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant’s equity awards.  Notwithstanding the foregoing, to the extent the Company submits any payment or benefit payable to the Participant under this Plan or otherwise to the Company’s stockholders for approval in accordance with Treasury Regulation Section 1.280G-1 Q&A 7, the foregoing provisions shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver of, such payments or benefits required by such vote will be applied without any application of discretion by the Participant and in the order prescribed by this Section 6.
6

Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 6 will be made in writing by the Company’s independent public accountants immediately prior to the Change in Control or such other person or entity to which the parties mutually agree (the “Firm”), whose determination will be conclusive and binding upon the Participant and the Company.  For purposes of making the calculations required by this Section 6 the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Participant and the Company will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section 6.  The Company will bear all costs the Firm may incur in connection with any calculations contemplated by this Section 6. 
7.Conditions to Receipt of Severance.
7.1 Release Agreement.  As a condition to receiving the Severance Benefits under this Plan, each Participant will be required to sign and not revoke a separation and release of claims agreement in a form reasonably satisfactory to the Company (the “Release”).  The Release will not include any post-employment restrictions beyond any such restrictions that a Participant has previously agreed to in written agreements with the Company.  In all cases, the Release must become effective and irrevocable no later than the 60th day following the Participant’s Involuntary Termination (the “Release Deadline Date”).  If the Release does not become effective and irrevocable by the Release Deadline Date, the Participant will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the Release becomes effective and irrevocable.
7.2 Other Requirements.  A Participant’s receipt of Severance Benefits will be subject to the Participant continuing to comply with the provisions of this Section 7 and the terms of any confidentiality, proprietary information and inventions agreement and any other agreement between the Participant and the Company under which the Participant has a material duty or obligation to the Company.  Severance Benefits under this Plan will terminate immediately for a Participant if the Participant, at any time, violates any such agreement and/or the provisions of this Section 7.
8.Timing of Severance Benefits.  Provided that the Release becomes effective and irrevocable by the Release Deadline Date and subject to Section 10, the Severance Benefits will be paid (or in the case of Severance Benefits scheduled to be paid installments, will commence) on the first Company payroll date following the Release Deadline Date (such payment date, the “Severance Start Date”), and any severance payments or benefits otherwise payable to the Participant during the period immediately following the Participant’s termination of employment with the Company through the Severance Start Date will be paid in a lump sum to the Participant on the Severance Start Date, with any remaining payments to be made as provided in this Plan.    
9.Exclusive Benefit.  The benefits provided under this Plan shall be the exclusive benefit for a Participant related to termination of employment and/or change in control.  For the avoidance of doubt, if a Participant was due benefits under a separate agreement because of a separation prior to a Change in Control, and the separation qualifies as an Involuntary Termination under the Plan, then such Participant shall only receive the superior of the applicable benefits, on a benefit-by-benefit basis. 
7

10.Section 409A.
10.1 Notwithstanding anything to the contrary in this Plan, no severance payments or benefits to be paid or provided to a Participant, if any, under this Plan that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A of the Code, and the final regulations and any guidance promulgated thereunder (“Section 409A”) (together, the “Deferred Payments”) will be paid or provided until the Participant has a “separation from service” within the meaning of Section 409A.  Similarly, no severance payable to a Participant, if any, under this Plan that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A1(b)(9) will be payable until the Participant has a “separation from service” within the meaning of Section 409A.
10.2 It is intended that none of the severance payments or benefits under this Plan will constitute Deferred Payments but rather will be exempt from Section 409A as a payment that would fall within the “short-term deferral period” as described in Section 10.3 below or resulting from an involuntary separation from service as described in Section 10.4 below.  In no event will a Participant have discretion to determine the taxable year of payment of any Deferred Payment.
10.3 Notwithstanding anything to the contrary in this Plan, if a Participant is a “specified employee” within the meaning of Section 409A at the time of the Participant’s separation from service (other than due to death), then the Deferred Payments, if any, that are payable within the first 6 months following the Participant’s separation from service, will become payable on the date 6 months and 1 day following the date of the Participant’s separation from service.  All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, in the event of the Participant’s death following the Participant’s separation from service, but before the 6 month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Participant’s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under this Plan is intended to constitute a separate payment under Section 1.409A-2(b)(2) of the Treasury Regulations.
10.4 Any amount paid under this Plan that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of Section 10 above.
10.5 Any amount paid under this Plan that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of Section 10 above.
8

10.6 The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the payments and benefits to be provided under the Plan will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be exempt.  Notwithstanding anything to the contrary in the Plan, including but not limited to Sections 12 and 15, the Company reserves the right to amend the Plan as it deems necessary or advisable, in its sole discretion and without the consent of the Participants, to comply with Section 409A or to avoid income recognition under Section 409A prior to the actual payment of benefits under the Plan or imposition of any additional tax.  In no event will the Company reimburse a Participant for any taxes that may be imposed on the Participant as result of Section 409A.
11.Withholdings.  The Company will withhold from any payments or benefits under the Plan all applicable U.S. federal, state, local and non-U.S. taxes required to be withheld and any other required payroll deductions.
12.Administration.  The Company is the administrator of the Plan (within the meaning of section 3(16)(A) of ERISA).  The Plan will be administered and interpreted by the Administrator (in its sole discretion).  The Administrator is the “named fiduciary” of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity.  Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law.  In accordance with Section 2.1, the Administrator (a) may, in its sole discretion and on such terms and conditions as it may provide, delegate in writing to one or more officers of the Company all or any portion of its authority or responsibility with respect to the Plan, and (b) has the authority to act for the Company (in a non-fiduciary capacity) as to any matter pertaining to the Plan; provided, however, that any Plan amendment or termination or any other action that reasonably could be expected to increase materially the cost of the Plan must be approved by the Board.
13.Eligibility to Participate.  To the extent that the Administrator has delegated administrative authority or responsibility to one or more officers of the Company in accordance with Sections 2.1 and 12, each such officer will not be excluded from participating in the Plan if otherwise eligible, but he or she is not entitled to act upon or make determinations regarding any matters pertaining specifically to his or her own benefit or eligibility under the Plan.  The Administrator will act upon and make determinations regarding any matters pertaining specifically to the benefit or eligibility of each such officer under the Plan.
9

14.Term.  This Plan will be effective on the Effective Date and automatically terminate on the date that is 24 months following the effective date of a Change in Control (the “Automatic Termination Date”); provided, however, the Plan may be terminated earlier in accordance with Section 15.  If the Participant becomes entitled to benefits during the term of this Plan, the Plan will not terminate with respect to such Participant until all of the obligations of the Company and such Participant with respect to this Plan have been satisfied.  If an initial occurrence of an act or omission by the Company (or its successor) constituting the grounds for  Good Reason for a Participant has occurred (the “Initial Grounds”), and the expiration date of the Company cure period (as such term is used in the Good Reason definition) with respect to such Initial Grounds could occur following Automatic Termination Date, then the term of the Plan will extend automatically through the date that is 30 days following the expiration of such cure period, but such extension of the term shall only apply with respect to the Initial Grounds.
15.Amendment or Termination.  The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any time without advance notice to any Participant and without regard to the effect of the amendment or termination on any Participant or on any other individual.  Any amendment or termination of the Plan will be in writing.  Notwithstanding the foregoing, any amendment to the Plan that (a) causes an individual or group of individuals to cease to be Participants or (b) reduces or alters to the detriment of a Participant the Severance Benefits potentially payable to that Participant (including, without limitation, imposing additional conditions or modifying the timing of payment), will not be effective unless it both is approved by the Administrator and communicated to the affected individual(s) in writing at least 90 days prior to the effective date of the amendment or termination, and once a Participant has incurred an Involuntary Termination, no amendment or termination of the Plan may, without that Participant’s written consent, reduce or alter to the detriment of the Participant, the Severance Benefits payable to that Participant.  In addition, notwithstanding the preceding, upon or after a Change in Control, the Company may not, without a Participant’s written consent, amend or terminate the Plan in any way, nor take any other action, that (i) prevents that Participant from becoming eligible for the Severance Benefits under the Plan, or (ii) reduces or alters to the detriment of the Participant the Severance Benefits payable, or potentially payable, to a Participant under the Plan (including, without limitation, imposing additional conditions).  Any action of the Company in amending or terminating the Plan will be taken in a non-fiduciary capacity. 
10

16.Claims and Appeals.
(a)Claims Procedure.  Any employee or other person who believes he or she is entitled to any payment under the Plan may submit a claim in writing to the Administrator within 90 days of the earlier of (i) the date the claimant learned the amount of his or her benefits under the Plan or (ii) the date the claimant learned that he or she will not be entitled to any benefits under the Plan.  If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based.  The notice also will describe any additional information needed to support the claim and the Plan’s procedures for appealing the denial.  The denial notice will be provided within 90 days after the claim is received.  If special circumstances require an extension of time (up to 90 days), written notice of the extension will be given within the initial 90 day period.  This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim.
(b)Appeal Procedure.  If the claimant’s claim is denied, the claimant (or his or her authorized representative) may apply in writing to the Administrator for a review of the decision denying the claim.  Review must be requested within 60 days following the date the claimant received the written notice of their claim denial or else the claimant loses the right to review.  The claimant (or representative) then has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing.  The Administrator will provide written notice of its decision on review within 60 days after it receives a review request.  If additional time (up to 60 days) is needed to review the request, the claimant (or representative) will be given written notice of the reason for the delay.  This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision.  If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based.  The notice also will include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant’s right to bring an action under Section 502(a) of ERISA.
17.Attorneys’ Fees.  The parties shall each bear their own expenses, legal fees and other fees incurred in connection with this Plan.  
18.Source of Payments.  All payments under the Plan will be paid from the general funds of the Company; no separate fund will be established under the Plan, and the Plan will have no assets.  No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company.
19.Inalienability.  In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell, transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan.  At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process.
11

20.No Enlargement of Employment Rights.  Neither the establishment or maintenance or amendment of the Plan, nor the making of any benefit payment hereunder, will be construed to confer upon any individual any right to continue to be an employee of the Company.  The Company expressly reserves the right to discharge any of its employees at any time, with or without cause.  However, as described in the Plan, a Participant may be entitled to benefits under the Plan depending upon the circumstances of his or her termination of employment.
21.Successors.  Any successor to the Company of all or substantially all of the Company’s business and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under the Plan, the term “Company” will include any successor to the Company’s business and/or assets which become bound by the terms of the Plan by operation of law, or otherwise.
22.Applicable Law.  The provisions of the Plan will be construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the state of California (but not its conflict of laws provisions).
23.Severability.  If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included.
24.Headings.  Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof.
25.Indemnification.  The Company hereby agrees to indemnify and hold harmless the officers and employees of the Company, and the members of its Board, from all losses, claims, costs or other liabilities arising from their acts or omissions in connection with the administration, amendment or termination of the Plan, to the maximum extent permitted by applicable law.  This indemnity will cover all such liabilities, including judgments, settlements and costs of defense.  The Company will provide this indemnity from its own funds to the extent that insurance does not cover such liabilities.  This indemnity is in addition to and not in lieu of any other indemnity provided to such person by the Company.
12

26.Additional Information.
						
	Plan Name:	Marvell Technology Group Ltd. Change in Control Severance Plan

	Plan Sponsor:
	Marvell Technology Group Ltd.

		c/o Marvell Semiconductor, Inc., Attn: Chief Legal Officer 

		5488 Marvell Lane  
		Santa Clara, CA 95054

	Identification Numbers:
	EIN: 77-0398669

		PLAN:  501

	Plan Year:
	Company’s fiscal year

	Plan Administrator:
	Marvell Technology Group Ltd.

		Attention: Administrator of the Marvell Technology Group Ltd. Change in Control Severance Plan

		c/o Marvell Semiconductor, Inc.

		5488 Marvell Lane
		Santa Clara, CA 95054
		408-222-2500
	Agent for Service of Legal Process:
	Marvell Technology Group Ltd.

		c/o Marvell Semiconductor, Inc. Attn: Chief Legal Officer

		5488 Marvell Lane
		Santa Clara, CA 95054
		408-222-2500
		Service of process also may be made upon the Administrator.
	Type of Plan
	Severance Plan/Employee Welfare Benefit Plan

	Plan Costs
	The cost of the Plan is paid by the Employer.

27.Statement of ERISA Rights.
As a Participant under the Plan, you have certain rights and protections under ERISA:
(a) You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of Labor.  These documents are available for your review in the Company’s Human Resources Department.
(b) You may obtain copies of all Plan documents and other Plan information upon written request to the Administrator.  A reasonable charge may be made for such copies.
13

In addition to creating rights for Participants, ERISA imposes duties upon the people who are responsible for the operation of the Plan.  The people who operate the Plan (called “fiduciaries”) have a duty to do so prudently and in the interests of you and the other Participants.  No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA.  If your claim for payments or benefits under the Plan is denied, in whole or in part, you must receive a written explanation of the reason for the denial.  You have the right to have the denial of your claim reviewed.  (The claim review procedure is explained in Section 16 above.)
Under ERISA, there are steps you can take to enforce the above rights.  For example, if you request materials and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent due to reasons beyond the control of the Administrator.  If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court.  If it should happen that you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.
In any case, the court will decide who will pay court costs and legal fees.  If you are successful, the court may order the person you have sued to pay these costs and fees.  If you lose, the court may order you to pay these costs and fees, for example, if it finds that your claim is frivolous.
If you have any questions regarding the Plan, please contact the Administrator.  If you have any questions about this statement or about your rights under ERISA, you may contact the nearest area office of the Employee Benefits Security Administration (formerly the Pension and Welfare Benefits Administration), U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210.  You also may obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.
        

14

TIER 1
Appendix A
Marvell Technology Group Ltd. Change in Control Severance Plan
Participation Agreement
Marvell Technology Group Ltd. (the “Company”) is pleased to inform you, ________________________, that you have been selected to participate in the Company’s Change in Control Severance Plan (the “Plan”) as a Participant.  
A copy of the Plan was delivered to you with this Participation Agreement.  Your participation in the Plan is subject to all of the terms and conditions of the Plan.  The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.
In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement and return it to [NAME] no later than [DATE].  
In the event of a Change in Control where the successor corporation does not assume your Equity Awards or substitute Equity Awards for substantially similar awards with the same or more favorable vesting schedule as your Equity Awards, then your Equity Awards will accelerate and vest in full in accordance with Section 3 of the Plan.
Also, the Plan describes in detail certain circumstances under which you may become eligible for certain Severance Benefits under Section 5 of the Plan if, during the Change in Control Period, you incur an Involuntary Termination.  If you become eligible for Severance Benefits as described in the Plan, then subject to the terms and conditions of the Plan, you will receive: 
1. Cash Severance Benefits.  
a. Base Salary. A lump-sum payment (less applicable withholding taxes) equal to 24 months of your annual base salary as in effect immediately prior to your Involuntary Termination (or if your Involuntary Termination is a termination for Good Reason due to a material reduction in your level of annual base salary, your annual base salary as in effect immediately prior to such reduction) or, if greater, at the level in effect immediately prior to the Change in Control.
b. Bonus.  A lump-sum payment equal to 200% of your annual target bonus for the fiscal year in which your Involuntary Termination occurs or, if greater, your annual target bonus in effect immediately prior to the Change in Control.
c. Pro-Rata Bonus.  A lump-sum payment equal to your annual target bonus for the fiscal year in which your Involuntary Termination occurs, pro-rated for the number of full months employed during the fiscal year.
         

2. Equity Award Vesting Acceleration.  100% of your then-outstanding and unvested Equity Awards will become vested in full.  If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then the Equity Award will vest as to 100% of the amount of the Equity Award assuming the performance criteria had been achieved at target levels for the relevant performance period(s); provided however, that (A) if there is no “target” level, then the number that will vest shall be 100% of the maximum amount that could vest with respect to that relevant measurement period(s); and (B) if the performance period has been completed and the actual performance achieved is greater than the target level, then the number that will vest shall be 100% of the amount that would vest based on that actual performance achievement level with respect to that relevant measurement period; and (C) if the performance criteria is a Total Shareholder Return (“TSR”) or other measure based on the value of the Company’s stock, the amount that will vest will be calculated as if the measurement period ended on the date of the Change in Control (and including the final closing price of the Company’s stock on such date). Any Company stock options and stock appreciation rights shall thereafter remain exercisable following the Employee’s employment termination for the period prescribed in the respective option and stock appreciation right agreements.
3. Continued Medical Benefits.  Your reimbursement of continued health coverage under COBRA or taxable monthly payment in lieu of reimbursement, as applicable, and as described in Section 5.3 of the Plan will be provided for a period of 24 months following your termination of employment.  Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.
In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period.
By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan.  Your signature below confirms that: (1) you have received a copy of the Change in Control Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the Change in Control Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) if you have previously entered into a Participation Agreement with the Company then you are revoking your prior Participation Agreement.
         

									
	MARVELL TECHNOLOGY GROUP LTD.
		PARTICIPANT

			
			
	Signature
		Signature

			
			
	Name
		Date
			
			
	Title
		

Attachment: Marvell Technology Group Ltd. Change in Control Severance Plan and Summary Plan Description

[Signature Page to the Participation Agreement]

         

TIER 2
Appendix A
Marvell Technology Group Ltd. Change in Control Severance Plan
Participation Agreement
Marvell Technology Group Ltd. (the “Company”) is pleased to inform you, ________________________, that you have been selected to participate in the Company’s Change in Control Severance Plan (the “Plan”) as a Participant.  
A copy of the Plan was delivered to you with this Participation Agreement.  Your participation in the Plan is subject to all of the terms and conditions of the Plan.  The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.
In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement and return it to [NAME] no later than [DATE].  
In the event of a Change in Control where the successor corporation does not assume your Equity Awards or substitute Equity Awards for substantially similar awards with the same or more favorable vesting schedule as your Equity Awards, then your Equity Awards will accelerate and vest in full in accordance with Section 3 of the Plan.
Also, the Plan describes in detail certain circumstances under which you may become eligible for certain Severance Benefits under Section 5 of the Plan if, during the Change in Control Period, you incur an Involuntary Termination.  If you become eligible for Severance Benefits as described in the Plan, then subject to the terms and conditions of the Plan, you will receive: 
1.Cash Severance Benefits.  
a. Base Salary. A lump-sum payment (less applicable withholding taxes) equal to 18 months of your annual base salary as in effect immediately prior to your Involuntary Termination (or if your Involuntary Termination is a termination for Good Reason due to a material reduction in your level of annual base salary, your annual base salary as in effect immediately prior to such reduction) or, if greater, at the level in effect immediately prior to the Change in Control.
b. Bonus.  A lump-sum payment equal to 150% of your annual target bonus for the fiscal year in which your Involuntary Termination occurs or, if greater, your annual target bonus in effect immediately prior to the Change in Control.
c. Pro-Rata Bonus.  A lump-sum payment equal to your annual target bonus for the fiscal year in which your Involuntary Termination occurs, pro-rated for the number of full months employed during the fiscal year.
         

2.Equity Award Vesting Acceleration.  100% of your then-outstanding and unvested Equity Awards will become vested in full.  If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then the Equity Award will vest as to 100% of the amount of the Equity Award assuming the performance criteria had been achieved at target levels for the relevant performance period(s); provided however, that (A) if there is no “target” level, then the number that will vest shall be 100% of the maximum amount that could vest with respect to that relevant measurement period(s); and (B) if the performance period has been completed and the actual performance achieved is greater than the target level, then the number that will vest shall be 100% of the amount that would vest based on that actual performance achievement level with respect to that relevant measurement period; and (C) if the performance criteria is a Total Shareholder Return (“TSR”) or other measure based on the value of the Company’s stock, the amount that will vest will be calculated as if the measurement period ended on the date of the Change in Control (and including the final closing price of the Company’s stock on such date). Any Company stock options and stock appreciation rights shall thereafter remain exercisable following the Employee’s employment termination for the period prescribed in the respective option and stock appreciation right agreements.
3.Continued Medical Benefits.  Your reimbursement of continued health coverage under COBRA or taxable monthly payment in lieu of reimbursement, as applicable, and as described in Section 5.3 of the Plan will be provided for a period of 18 months following your termination of employment.  Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.
In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period.
By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan.  Your signature below confirms that: (1) you have received a copy of the Change in Control Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the Change in Control Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) if you have previously entered into a Participation Agreement with the Company then you are revoking your prior Participation Agreement.
         

									
	MARVELL TECHNOLOGY GROUP LTD.
		PARTICIPANT

			
			
	Signature
		Signature

			
			
	Name
		Date
			
			
	Title
		

Attachment: Marvell Technology Group Ltd. Change in Control Severance Plan and Summary Plan Description

[Signature Page to the Participation Agreement]

         

TIER 3
Appendix A
Marvell Technology Group Ltd. Change in Control Severance Plan
Participation Agreement
Marvell Technology Group Ltd. (the “Company”) is pleased to inform you, ________________________, that you have been selected to participate in the Company’s Change in Control Severance Plan (the “Plan”) as a Participant.  
A copy of the Plan was delivered to you with this Participation Agreement.  Your participation in the Plan is subject to all of the terms and conditions of the Plan.  The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.
In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement and return it to [NAME] no later than [DATE].  
In the event of a Change in Control where the successor corporation does not assume your Equity Awards or substitute Equity Awards for substantially similar awards with the same or more favorable vesting schedule as your Equity Awards, then your Equity Awards will accelerate and vest in full in accordance with Section 3 of the Plan.
Also, the Plan describes in detail certain circumstances under which you may become eligible for certain Severance Benefits under Section 5 of the Plan if, during the Change in Control Period, you incur an Involuntary Termination.  If you become eligible for Severance Benefits as described in the Plan, then subject to the terms and conditions of the Plan, you will receive: 
1.Cash Severance Benefits.  
a. Base Salary. A lump-sum payment (less applicable withholding taxes) equal to 12 months of your annual base salary as in effect immediately prior to your Involuntary Termination (or if your Involuntary Termination is a termination for Good Reason due to a material reduction in your level of annual base salary, your annual base salary as in effect immediately prior to such reduction) or, if greater, at the level in effect immediately prior to the Change in Control.
b. Bonus.  A lump-sum payment equal to 100% of your annual target bonus for the fiscal year in which your Involuntary Termination occurs or, if greater, your annual target bonus in effect immediately prior to the Change in Control.
c. Pro-Rata Bonus.  A lump-sum payment equal to your annual target bonus for the fiscal year in which your Involuntary Termination occurs, pro-rated for the number of full months employed during the fiscal year.

         

2.Equity Award Vesting Acceleration.  100% of your then-outstanding and unvested Equity Awards will become vested in full.  If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then the Equity Award will vest as to 100% of the amount of the Equity Award assuming the performance criteria had been achieved at target levels for the relevant performance period(s); provided however, that (A) if there is no “target” level, then the number that will vest shall be 100% of the maximum amount that could vest with respect to that relevant measurement period(s); and (B) if the performance period has been completed and the actual performance achieved is greater than the target level, then the number that will vest shall be 100% of the amount that would vest based on that actual performance achievement level with respect to that relevant measurement period; and (C) if the performance criteria is a Total Shareholder Return (“TSR”) or other measure based on the value of the Company’s stock, the amount that will vest will be calculated as if the measurement period ended on the date of the Change in Control (and including the final closing price of the Company’s stock on such date). Any Company stock options and stock appreciation rights shall thereafter remain exercisable following the Employee’s employment termination for the period prescribed in the respective option and stock appreciation right agreements.
3.Continued Medical Benefits.  Your reimbursement of continued health coverage under COBRA or taxable monthly payment in lieu of reimbursement, as applicable, and as described in Section 5.3 of the Plan will be provided for a period of 12 months following your termination of employment.  Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.
In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period.
By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan.  Your signature below confirms that: (1) you have received a copy of the Change in Control Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the Change in Control Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) if you have previously entered into a Participation Agreement with the Company then you are revoking your prior Participation Agreement.
         

									
	MARVELL TECHNOLOGY GROUP LTD.
		PARTICIPANT

			
			
	Signature
		Signature

			
			
	Name
		Date
			
			
	Title
		

Attachment: Marvell Technology Group Ltd. Change in Control Severance Plan and Summary Plan Description

[Signature Page to the Participation Agreement]
         

 TIER 4
Appendix A
Marvell Technology Group Ltd. Change in Control Severance Plan
Participation Agreement
Marvell Technology Group Ltd. (the “Company”) is pleased to inform you, ________________________, that you have been selected to participate in the Company’s Change in Control Severance Plan (the “Plan”) as a Participant.  
A copy of the Plan was delivered to you with this Participation Agreement.  Your participation in the Plan is subject to all of the terms and conditions of the Plan.  The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.
In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement and return it to [NAME] no later than [DATE].  
In the event of a Change in Control where the successor corporation does not assume your Equity Awards or substitute Equity Awards for substantially similar awards with the same or more favorable vesting schedule as your Equity Awards, then your Equity Awards will accelerate and vest in full in accordance with Section 3 of the Plan.
Also, the Plan describes in detail certain circumstances under which you may become eligible for certain Severance Benefits under Section 5 of the Plan if, during the Change in Control Period, you incur an Involuntary Termination.  If you become eligible for Severance Benefits as described in the Plan, then subject to the terms and conditions of the Plan, you will receive: 
1.Cash Severance Benefits.  
a. Base Salary. A lump-sum payment (less applicable withholding taxes) equal to 6 months of your annual base salary as in effect immediately prior to your Involuntary Termination (or if your Involuntary Termination is a termination for Good Reason due to a material reduction in your level of annual base salary, your annual base salary as in effect immediately prior to such reduction) or, if greater, at the level in effect immediately prior to the Change in Control.
b. Bonus.  A lump-sum payment equal to 50% of your annual target bonus for the fiscal year in which your Involuntary Termination occurs or, if greater, your annual target bonus in effect immediately prior to the Change in Control.
c. Pro-Rata Bonus.  A lump-sum payment equal to your annual target bonus for the fiscal year in which your Involuntary Termination occurs, pro-rated for the number of full months employed during the fiscal year.
         

2.Equity Award Vesting Acceleration.  100% of your then-outstanding and unvested Equity Awards will become vested in full.  If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then the Equity Award will vest as to 100% of the amount of the Equity Award assuming the performance criteria had been achieved at target levels for the relevant performance period(s); provided however, that (A) if there is no “target” level, then the number that will vest shall be 100% of the maximum amount that could vest with respect to that relevant measurement period(s); and (B) if the performance period has been completed and the actual performance achieved is greater than the target level, then the number that will vest shall be 100% of the amount that would vest based on that actual performance achievement level with respect to that relevant measurement period; and (C) if the performance criteria is a Total Shareholder Return (“TSR”) or other measure based on the value of the Company’s stock, the amount that will vest will be calculated as if the measurement period ended on the date of the Change in Control (and including the final closing price of the Company’s stock on such date). Any Company stock options and stock appreciation rights shall thereafter remain exercisable following the Employee’s employment termination for the period prescribed in the respective option and stock appreciation right agreements.
3.Continued Medical Benefits.  Your reimbursement of continued health coverage under COBRA or taxable monthly payment in lieu of reimbursement, as applicable, and as described in Section 5.3 of the Plan will be provided for a period of 6 months following your termination of employment.  Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.
In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period.
By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan.  Your signature below confirms that: (1) you have received a copy of the Change in Control Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the Change in Control Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) if you have previously entered into a Participation Agreement with the Company then you are revoking your prior Participation Agreement.
         

									
	MARVELL TECHNOLOGY GROUP LTD.
		PARTICIPANT

			
			
	Signature
		Signature

			
			
	Name
		Date
			
			
	Title
		

Attachment: Marvell Technology Group Ltd. Change in Control Severance Plan and Summary Plan Description

[Signature Page to the Participation Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]